The Future Is Fluid
Liquid Biopsy Has Proven Its Mettle in the Fight against NSCLC and May Soon Also Be Standard of Care in Other Cancers
Genomics Brings Heavy Lifting to Immuno-Oncology
The Synergy of Two Burgeoning Fields Will Lead to Improved Precision Medicine
Singling Out RNA Biomarkers in Situ
ACD’s ISH Platform Achieves Single-Base Resolution and Retains Morphological Context
Microanalyte MDx Goes Mainstream
Nucleic Acid Analytes Are Reliable Sources of Data for Diagnostic Calculations
For full access to this article login to GEN Select now.
Exceptional Responders: The “N of 1” Paradigm
Hope for Better Cancer Treatments May Lie in Those Patients Who Respond Exceptionally Well
- We have all heard stories about the single patient who survives a deadly cancer in response to a particular drug, in contrast to other patients receiving the same drug who succumb to the disease. These patients may include heavily pretreated cancer patients for whom other drugs have failed, ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.